Loading the page…
Nasdaq 100
Amgen Inc., Health Care
$466.01
+1.15% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1B | $8.6B | $9.9B | $9.6B | $9.2B | $8.1B | $9.1B | $8.5B |
| Gross margin | 72.0% | 68.2% | 69.8% | 67.8% | 67.2% | 63.6% | 65.7% | 61.1% |
| Operating margin | 35.0% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 30.9% |
| 27.6% |
| 26.4% |
| 28.9% |
| 14.5% |
| 25.4% |
| 24.1% |
| Net margin | 23.6% | 21.1% | 13.5% | 33.7% | 15.6% | 21.2% | 6.9% | 33.3% |
|---|
| EPS, diluted | $4.37 | $3.34 | $2.45 | $5.93 | $2.65 | $3.20 | $1.17 | $5.22 |
|---|
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | AMGN | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | 3.5% | 61% |
| Book yield (book value ÷ price) | 4.6% | 16% |
| Free cash flow yield | 3.2% | 60% |
| Buyback yield | 0.0% | 0% |
| Revenue growth, a year | 10.0% | 42% |
| EPS growth, a year | 88.2% | 81% |
| Return on equity | 74.8% | 92% |
| Return on assets | 9.1% | 45% |
| Net margin | 23.0% | 65% |
| Liabilities ÷ assets | 87.8% | 93% |
| Past year, skipping last month | 43.5% | 74% |
| Past 6 months, skipping last month | 25.1% | 80% |
| Volatility, a year's worth | 33.8% | 39% |
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Modeled on each investor's published approach, not their real picks. Ask opens a chat with that bot about AMGN in Claude or ChatGPT. Connect your assistant →
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients…
From Yahoo Finance, amgen.com
Dow Jones Futures Rise After Market Sell-Off; How Midterm Elections May Swing StocksInvestor's Business Daily, 11m ago
Looking For Growth, Income, and Stability? This Stock Could Offer All 3Motley Fool, Oct 31
Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey NarrativeSimply Wall St., Oct 31
New CFO Appointment Could Be A Big Moment For Mattel (MAT)Simply Wall St., Oct 31
Big Homes, Big LoansBarrons.com, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Dow Jones Futures Rise After Market Sell-Off; How Midterm Elections May Swing StocksInvestor's Business Daily, 11m ago
Looking For Growth, Income, and Stability? This Stock Could Offer All 3Motley Fool, Oct 31
Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey NarrativeSimply Wall St., Oct 31
New CFO Appointment Could Be A Big Moment For Mattel (MAT)Simply Wall St., Oct 31
Big Homes, Big LoansBarrons.com, Oct 30
Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto HeistBarchart, Oct 30
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockBarrons.com, Oct 30
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthZacks, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Picked by YouTube search, not by us. Someone else's view, not advice.